Literature DB >> 9419816

Identification and characterisation of a human calmodulin-stimulated phosphodiesterase PDE1B1.

J Yu1, S L Wolda, A L Frazier, V A Florio, T J Martins, P B Snyder, E A Harris, K N McCaw, C A Farrell, B Steiner, J K Bentley, J A Beavo, K Ferguson, R Gelinas.   

Abstract

A cDNA encoding a calmodulin-stimulated 3',5'-cyclic nucleotide phosphodiesterase (PDE) was isolated from a human brain cDNA library. The cDNA, designated HSPDE1B1, encoded a protein of 536 amino acids that shared 96% sequence identity with the bovine "63 kDa" calmodulin-stimulated PDE. The recombinant protein had cyclic nucleotide phosphodiesterase activity that was stimulated approximately 2-fold by Ca2+/calmodulin and preferred cGMP as substrate. In addition, the enzymatic activity of HSPDE1B1 was inhibited by phosphodiesterase inhibitors with potencies similar to that displayed toward the bovine PDE1 enzymes: IBMX approximately equal to 8-methoxymethyl-IBMX > vinpocetine approximately equal to zaprinast > cilostamide > rolipram. HSPDE1B1 mRNA was found predominantly in the brain. Lower mRNA levels were found in heart and skeletal muscle. In situ hybridisation of brain revealed expression of HSPDE1B1 predominately in neuronal cells of the cerebellum, hippocampus and caudate. The HSPDE1B1 gene was mapped to human chromosome 12. A partial genomic sequence of HSPDE1B1 was isolated and shown to contain two splice junctions that are conserved in the rat PDE4 and the Drosophila dunce genes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9419816     DOI: 10.1016/s0898-6568(97)00046-6

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  20 in total

Review 1.  Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies.

Authors:  Adam Lerner; Paul M Epstein
Journal:  Biochem J       Date:  2006-01-01       Impact factor: 3.857

2.  Orphanin FQ/nociceptin not only blocks but also reverses behavioral adaptive changes induced by repeated cocaine in mice.

Authors:  David Bebawy; Paul Marquez; Seroje Samboul; Drupad Parikh; Abdul Hamid; Kabirullah Lutfy
Journal:  Biol Psychiatry       Date:  2010-03-31       Impact factor: 13.382

Review 3.  An update on vinpocetine: New discoveries and clinical implications.

Authors:  Yi-Shuai Zhang; Jian-Dong Li; Chen Yan
Journal:  Eur J Pharmacol       Date:  2017-11-26       Impact factor: 4.432

4.  Phosphodiesterase-1b deletion confers depression-like behavioral resistance separate from stress-related effects in mice.

Authors:  J R Hufgard; M T Williams; C V Vorhees
Journal:  Genes Brain Behav       Date:  2017-06-07       Impact factor: 3.449

5.  A critical role of the nitric oxide/cGMP pathway in corticostriatal long-term depression.

Authors:  P Calabresi; P Gubellini; D Centonze; G Sancesario; M Morello; M Giorgi; A Pisani; G Bernardi
Journal:  J Neurosci       Date:  1999-04-01       Impact factor: 6.167

6.  Selective up-regulation of PDE1B2 upon monocyte-to-macrophage differentiation.

Authors:  Andrew T Bender; Cari L Ostenson; Edith H Wang; Joseph A Beavo
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-29       Impact factor: 11.205

7.  Cyclic nucleotide signaling in polycystic kidney disease.

Authors:  Xiaofang Wang; Christopher J Ward; Peter C Harris; Vicente E Torres
Journal:  Kidney Int       Date:  2009-11-18       Impact factor: 10.612

Review 8.  Phosphodiesterases as therapeutic targets for Alzheimer's disease.

Authors:  Ana García-Osta; Mar Cuadrado-Tejedor; Carolina García-Barroso; Julen Oyarzábal; Rafael Franco
Journal:  ACS Chem Neurosci       Date:  2012-10-01       Impact factor: 4.418

9.  cGMP Signaling, Phosphodiesterases and Major Depressive Disorder.

Authors:  Gillian W Reierson; Shuyu Guo; Claudio Mastronardi; Julio Licinio; Ma-Li Wong
Journal:  Curr Neuropharmacol       Date:  2011-12       Impact factor: 7.363

10.  Prediction and validation of a mechanism to control the threshold for inhibitory synaptic plasticity.

Authors:  Yuichi Kitagawa; Tomoo Hirano; Shin-ya Kawaguchi
Journal:  Mol Syst Biol       Date:  2009-06-16       Impact factor: 11.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.